EXOZHIGH SIGNALFINANCIAL10-K

EXOZ experienced severe financial deterioration with cash reserves plummeting 69% to $3.0M while R&D expenses doubled and operating losses increased 64% to $9.7M.

The company is burning through cash at an alarming rate with only $3.0M remaining versus $9.7M a year ago, creating potential going concern issues. The doubling of R&D expenses to $3.7M combined with widening losses suggests EXOZ is in a critical phase of development that requires significant capital investment, but the rapid cash depletion timeline may force difficult financing decisions or operational changes soon.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

EXOZ's financial position deteriorated dramatically across all key metrics, with cash and equivalents falling 69% to just $3.0M while R&D expenses nearly doubled to $3.7M, driving operating losses up 64% to $9.7M. Total assets shrunk 54% and stockholders' equity declined 67% to $3.4M, reflecting the company's cash burn and accumulated losses. Despite a 24% improvement in operating cash flow to -$6.5M and reduced capital expenditures, the overall picture signals a company in financial distress with limited runway to fund operations without additional capital.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+98.4%
$1.9M$3.7M

R&D investment increased 98.4% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
-68.7%
$9.7M$3.0M

Cash declined 68.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-67.4%
$10.4M$3.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
-63.8%
-$5.9M-$9.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Assets
Balance Sheet
-63.6%
$10.8M$3.9M

Current assets declined 63.6% — monitor working capital adequacy and short-term liquidity.

Capital Expenditure
Cash Flow
-57.1%
$396K$170K

Capex reduced 57.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
-56.3%
-$5.9M-$9.2M

Net income declined 56.3% — review whether driven by operations, interest costs, or non-recurring items.

Total Assets
Balance Sheet
-54.2%
$13.0M$6.0M

Total assets contracted 54.2% — asset sales, write-downs, or balance sheet optimization underway.

Operating Cash Flow
Cash Flow
+23.6%
-$8.5M-$6.5M

Operating cash flow grew 23.6% — strong conversion of earnings to cash, healthy business fundamentals.

Current Liabilities
Balance Sheet
+17.5%
$1.3M$1.6M

Current liabilities rose 17.5% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
As of March 29, 2026, the number of outstanding shares of Common Stock was 8,478,992 .
The closing price of a share of Common Stock on March 26, 2026 on the Nasdaq Stock Market was $ 7.23 .
and, where appropriate, together with its wholly owned subsidiaries.
Business Overview Chemicals are ubiquitous in modern life - they form the basis of medicines, fuels, plastics, food, and colors, among many other applications that together contribute to our ability to live the good life in the modern world.
As a best-of-both-worlds solution for future chemical production, eXoZymes believes it has developed technology that will allow us to harness more of the mechanisms that nature uses for biochemical production.
+7 more — sign up free →
REMOVED
The closing price of a share of Common Stock on March 29, 2025 on the Nasdaq Stock Market was $ 9.99 .
The registrant completed its initial public offering and listed its Common Stock for trading on the Nasdaq Stock Market on November 11, 2024, therefore no common shares were traded as of the last business day of the registrant s most recently completed second fiscal quarter.
and, where appropriate, together with its wholly owned subsidiary.
Business Overview Chemicals are ubiquitous and fundamental to our modern life - they are the basic building blocks of medicines, fuels, plastics, food, and colors, among many other applications that together contribute to our ability to live the good life in the modern world.
As a best-of-both-worlds solution for future chemical production, we at eXoZymes Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →